Key clinical point: A new gene expression signature for high-grade serous ovarian cancer is prognostic for overall survival.

Major finding: The median overall survival was 9.5 years, 5.4 years, 3.8 years, 3.2 years, and 2.3 years for patients in the first, second, third, fourth, and fifth quintiles of signature scores, respectively (hazard ratio for death per one gain of standard deviation in score, 2.35; P < .001).

Study details: A signature development and validation study using pretreatment formalin-fixed, paraffin-embedded tumor tissue from 3,769 women with high-grade serous ovarian cancer participating in 21 studies.

Disclosures: The research was funded by the National Institutes of Health/National Cancer Institute, the Canadian Institutes for Health Research, and the Department of Defense Ovarian Cancer Research Program. Some of the authors disclosed financial relationships with a range of companies.